araag2/HINT huggingface dataset:
Clinical trial NCT01063907 (phase 1/phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: kw-2478, bortezomib
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Accepts Healthy Volunteers: No

        Inclusion Criteria:

          1. Subjects with a confirmed diagnosis of Multiple Myeloma who have had one and no more
             than three prior regimens for MM to which they did not respond (failed) or from which
             they have relapsed.

          2. Signed either an IRB or IEC approved informed consent

          3. ECOG performance status of ≤ 2

          4. Life expectancy of at least 3 months

          5. M protein in either serum or urine, or free light chains if not measurable M protein
             in serum or urine, and clonal bone marrow plasma cells > 10%, and evidence of end
             organ damage

          6. Adequate hematologic status, liver and renal function

          7. Subjects of reproductive potential must agree to follow accepted pregnancy prevention
             methods during the study.

        Exclusion Criteria:

          1. No anti-cancer treatment for ≥ 4 weeks and no bortezomib treatment ≥ 60 days prior to
             receiving study drug

          2. Any other severe, acute or chronic illness

          3. No other prior or concurrent malignancy

          4. No immunosuppressant therapy
Clinical trial NCT01069341 (phase 1, status: completed)
Conditions: rubeosis iridis, proliferative diabetic retinopathy
ICD codes: H35.23, H35.20, H35.21, H35.22, E10.3553, E11.3553, E13.3553
Drugs: ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 years or over

          -  Subjects with diabetes mellitus

          -  Subjects with proliferative diabetic retinopathy induced rubeosis

          -  Be willing to undergo cataract surgery

          -  HgbA1c level < 12%

        Exclusion Criteria:

          -  History of glaucoma surgery

          -  Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis

          -  Intraocular surgery in the study eye within 60 days preceding Day 0

          -  History of prior pars plana vitrectomy in the study eye

          -  Positive pregnancy test

          -  HbA1c >12
Clinical trial NCT01871961 (phase 1, status: completed)
Conditions: rheumatoid arthritis (ra)
ICD codes: M05.9, M06.08, M06.00, M06.011, M06.012, M06.019, M06.021
Drugs: methotrexate (metoject® prefilled pen)
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Is a suitable candidate for treatment with Methotrexate for Rheumatoid Arthritis

          -  Male or female patient who is 16 years of age or older

        Exclusion Criteria:

          -  Is a female patient who is pregnant, trying to become pregnant, or breast feeding, or
             of childbearing potential, sexually active and not practicing a highly reliable method
             of birth control during the study and at least 6 months thereafter

          -  Has any history of hypersensitivity to the investigational medicinal product

          -  Has a history of or current inflammatory arthritis or rheumatic autoimmune disease
             other than Rheumatoid Arthritis (RA)

          -  Is unable to comprehend written labeling and training materials
Clinical trial NCT00081887 (phase 1, status: terminated)
Conditions: chronic lymphocytic leukemia, leukemia
ICD codes: C91.11, C91.12, C91.10, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: clofarabine
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Reason stopped: 
    low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with chronic lymphocytic leukemia (CLL), CLL/PLL (as defined by FAB), and PLL
             (B- and T-cell phenotypes) who have relapsed from or are refractory to at least one
             fludarabine-based regimen.

          2. Absolute neutrophil count (ANC) >= 1 x 10(9)/L and platelet count >= 50 x 10(9)/L

          3. Adequate liver function (total bilirubin <= 1.5 x ULN, SGPT <= 2.5 x ULN) and renal
             function (serum creatine <= 1.5 x ULN).

          4. ECOG performance status <= 2.

        Exclusion Criteria:

          1. Patients with NYHA >= grade 3 heart disease as assessed by history and/or physical
             examination

          2. Pregnant or breastfeeding women or patients who are unwilling or unable to practice
             adequate contraception.

          3. Chemotherapy within 4 weeks of starting therapy, or concurrent anticancer therapy
             (chemotherapy, radiotherapy, or biologic therapy)

          4. Other malignancy within 3 years except in situ carcinoma

          5. Unwilling or unable to provide informed consent

          6. Hypersensitivity to nucleoside analogues

          7. Other significant medical condition that compromises safety, compliance or study
             conduct, including but not limited to uncontrolled hypertension, unstable angina,
             congestive heart failure, myocardial infarction within 6 months, ventricular
             arrhythmia, diabetes, active infection, pulmonary fibrosis, and chronic hepatitis
Clinical trial NCT01486446 (phase 1/phase 2, status: completed)
Conditions: primary erythromelalgia, inherited erythromelalgia
ICD codes: I73.81
Drugs: xpf-002, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must have a Body Mass Index (BMI) of 18-40 kg/m2 (inclusive)

          -  Have primary or inherited erythromelalgia (IEM)

          -  Experience flares of pain in your feet or hands caused by erythromelalgia

          -  Be generally healthy (apart from your pain)

          -  Stop taking your usual pain medications and certain other medications for up to 11.5
             weeks

          -  Not be pregnant or breast-feeding

          -  Must be able and willing to provide informed consent and willing to comply with all
             study procedures and restrictions

        Exclusion Criteria:

          -  Must not be in constant pain (must not continually be in moderate pain, 3/10 or more)

          -  Coexistent source of pain from other conditions that may interfere with the study
             interpretation

          -  HIV, Hepatitis B or C

          -  Treatment for significant depression within 6 months of Screening

          -  Not willing to use adequate contraception

          -  Alcoholism, alcohol or substance abuse

          -  Presence or history of major psychiatric disturbance

          -  Any other condition or finding that may pose undue risk for participation

          -  Use of any other investigational drug in the 30 days prior to dosing

          -  Donation or loss of whole blood or plasma prior to dosing as follows: 50 mL to 499 mL
             within 30 days, or more than 499 mL within 56 days

          -  Employee or relative of an employee who is directly involved in the study
Clinical trial NCT00332085 (phase 1, status: terminated)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: chromium picolinate
SMILES: O=C(O[Cr](OC(=O)C1=CC=CC=N1)OC(=O)C1=CC=CC=N1)C1=CC=CC=N1
Reason stopped: 
    issues w/recruitment
  
Eligibility criteria:

        Inclusion Criteria:

        ICD-9 Diagnosis of TYpe 2 Diabetes (250.XX) for two years or less and treated with
        metformin Patients having completed dose titration of metformin as prescribed by their
        physician and have reached a stble dose between 1000-2550 mg per day for at least two
        months HbA1c: 7.0-10.5%

        Exclusion Criteria:

          -  Duration of metformin treatment longer than 1 year at start time of study medication
             Historical or current use of oral anti-diabetes (OAD) medication (other than
             metformin) or use of insulin History ofmyocardial infarction within the lat 6 months,
             unstable angina, uncontrollable hypertension with systolic greater than 180 or
             diastolic greater than 110.

        Clinical or objective finding suggestive of congestive heart failure. Individuals not
        receiving routine management by their primary car eproviders and/or endocrinologists for
        their type 2 diabetes, including routine ECG and ophthamological evaluations.

        Women of child-bearing age not using standard birth control measures. Hemoglobin <11 or >
        16; Hematocrig <32 or > 50; WBC <3,000 or >12,000; Platelets <150,000 or >500,000 Serum
        Creatinine >1.4 mg/dL; BUN >25 mg/dL Presence of greater than +1 protein on random
        macroscopic urinalysis at screening without a rule out of microalbuminuria Total bilirubin
        >1.5 mg/dL LFTs: AST>60 IU/L; ALT>65/L; Alkaline phosphatase >120 Iu/L. Isolated LFT
        elevations with an ultrasound diagnosis of non-alcoholic Steatohepatitis and a lab rule out
        of viral hepatitis will be included in the study with careful monitoring of LFTs.

        Subjects currently taking nutritional supplements, including multivatmin for study
        duration; subjects will be asked to discontinue any nutritional supplementation at the
        screening telephone interview 1 week prior to screening lab work and 4 week sprior to
        baseline lab work.

        Subjects taking lipid lowering medications except statins (i.e. niacin, fibrates, resins)
        due to possible chromium binding.
Clinical trial NCT01278810 (phase 1, status: unknown status)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: icaritin
SMILES: COC1=CC=C(C=C1)C1=C(O)C(=O)C2=C(O)C=C(O)C(CC=C(C)C)=C2O1
Eligibility criteria:

        Inclusion Criteria:

          1. Female, age ≥ 18 years old and ≤ 65 years old

          2. The patients with advanced breast tumors who are confirmed through histologic or
             cytologic diagnosis with ER positive or investigator think that subjects will benefit
             from the trial

          3. The advanced breast cancer patients which relapse or failure from previous standard
             treatment

          4. 19 ≤ BMI index ≤ 30

          5. No serious heart, liver,lung and kidney diseases

          6. Received at least once anti-cancer treatment (including chemotherapy, radiotherapy,
             biological or endocrine treatment). And the last treatment must be at least four weeks
             before study enrollment or more than 5 times half life. The surgery treatment must be
             more than three months

          7. Life expectancy of at least 12 weeks

          8. Patients which can cooperate to observe AE and efficacy

          9. No any other concurrent anti-cancer treatment

         10. A signed informed consent must be obtained prior to performing any study specific
             procedures

         11. ECOG Performance Status of 0,1

         12. Female:Women with childbearing potential must have a negative pregnancy test performed

        Exclusion Criteria:

          1. Have a known hypersensitivity to flavonoid drugs

          2. Hepatic:

               -  ALB >limit if normal

               -  TB> the upper limit of normal

               -  ALT and AST > upper limit of Normal

             Renal:

               -  Serum Creatinine > 1.5 times the upper limit of normal

             Bone marrow:

               -  Absolute neutrophil count (ANC) < 1.5 × 109/L

               -  Platelet count < 90 × 109/L

               -  Hemoglobin < 9 g/dL

          3. PT/APTT > 1.25 times the upper limit of normal

          4. Suffered from thrombotic disease

          5. Serum Ca > the upper limit of normal

          6. Not recovered from toxic effects of previous anti-cancer treatments or surgery

          7. Any serious or uncontrollable concomitant systemic disorder (such as unstable
             respiratory disorders, cardiovascular, hepatic or kidney disorders.) or active
             infection which will influence the clinical trial

          8. CNS metastases or invade requiring treatment for unstable status or various
             psychiatric disorders

          9. No malabsorption or other disease which will affect the drug
             absorption,distribution,metabolism and excretion

         10. Concurrent other malignancies with the exception of cervical cancer in situ or
             squamous Cell Carcinoma of the Skin
Clinical trial NCT01214655 (phase 1, status: terminated)
Conditions: acute leukemia
ICD codes: C91.01, C91.02, C92.01, C92.02, C92.41, C92.42, C92.51
Drugs: ly2523355
SMILES: CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)C1=CC=CC=C1
Reason stopped: 
    primary objective has been met in the absence of clinically meaningful remissions
  
Eligibility criteria:

        Inclusion Criteria:

        Dose escalation period for both schedules:

          -  Participants must have a confirmed diagnosis of acute leukemia regardless of sub-type
             and for whom experimental Phase 1 therapy is appropriate.

          -  Are greater than or equal to 18 years of age.

          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             scale.

          -  Females with childbearing potential must have had a negative urine or serum pregnancy
             test less than or equal to 7 days prior to the first dose of study drug.

        Dose confirmation period for both schedules:

          -  Participant must have a confirmed diagnosis of untreated acute myeloblastic leukemia
             (AML), should not be a candidate for standard therapy, and a clinical trial is a
             preferred treatment option or have acute AML that is relapsed or refractory to no more
             than 2 prior induction regimens. Hydroxyurea to control prior blast counts is not
             considered a prior regimen.

          -  Are greater than or equal to 60 years of age.

          -  Have a performance status of 0 or 1 on the ECOG scale.

          -  Females with childbearing potential must have had a negative urine or serum pregnancy
             test less than or equal to 7 days prior to the first dose of study drug.

        Exclusion Criteria:

          -  Have received treatment within 28 days of the initial dose of study drug with a drug
             that has not received regulatory approval for any indication.

          -  Participants with known central nervous system (CNS) leukemia by spinal fluid cytology
             or imaging. A lumbar puncture is not required unless CNS involvement is clinically
             suspected. Participants with signs or symptoms of leukemic meningitis or a history of
             leukemic meningitis must have a negative lumbar puncture within 2 weeks of study
             enrollment.

          -  Have other active malignancy (with the exception of basal and squamous cell skin
             cancer) at time of study entry.

          -  Have had an autologous or allogenic bone marrow transplant within 3 months. All organ
             toxicity must be resolved.

          -  Have evidence of graft-versus-host disease due to an allogenic bone marrow transplant.

          -  Have uncontrolled systemic infection.

          -  Females who are pregnant or lactating.

          -  Have known positive test results in human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBSAg), or hepatitis C antibodies (HCAb) (screening not required).
Clinical trial NCT00707707 (phase 1, status: completed)
Conditions: breast cancer, triple negative breast cancer, metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: azd2281, paclitaxel
SMILES: OC1=NN=C(CC2=CC(C(=O)N3CCN(CC3)C(=O)C3CC3)=C(F)C=C2)C2=CC=CC=C12, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  patients with histologically or cytologically diagnosed metastatic triple negative
             breast cancer (Oestrogen, progesterone and HER2 negative adenocarcinoma of the breast)

          -  Patients must have normal organ and bone marrow function, ECOG performance status of
             no more than 2

          -  Formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer
             must be available for central testing.

        Exclusion Criteria:

          -  Any chemotherapy, radiotherapy (except for palliative reasons) or investigational
             product, within 2 weeks from the last dose prior to study entry (or longer period,
             depending on the agent used)

          -  Major surgery within 4 weeks of starting the study, and must have recovered from any
             effects of major surgery

          -  Patients requiring treatment with the following:certain antibiotic drugs, St.John's
             Wort, carbamazepine, phenobarbitone, phenytoin, and certain protease inhibitors/
             non-nucleoside reverse transcriptase inhibitors used as components of HIV/AIDS
             treatment,

          -  Patients with second primary cancer; except adequately treated non-melanoma skin
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumours
             curatively treated with no evidence of disease for at least 5 years.
Clinical trial NCT01400451 (phase 1, status: terminated)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: ipilimumab (bms-734016), vemurafenib
SMILES: COC1=CC=CC=C1OCC(O)CO, CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1
Reason stopped: 
    more than 2 of 6 patients treated experienced dose limiting toxicities.
  
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Metastatic melanoma with activating V600 BRAF mutation

          -  Measurable Tumor

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1

        Exclusion Criteria:

          -  Autoimmune disease

          -  Active Brain Metastasis (must be stable after radiation for at least one month)

          -  Prior therapy with immune stimulating agents
Clinical trial NCT01030055 (phase 1, status: completed)
Conditions: neoplasms, cancer, tumors
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3
Drugs: tki258 (dovitinib)
SMILES: CN1CCN(CC1)C1=CC=C2N=C(NC2=C1)C1=C(N)C2=C(NC1=O)C=CC=C2F
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with an advanced solid tumor, except breast cancer,which has progressed
             despite standard therapy, or for which no standard therapy exists

          -  World Health Organization (WHO) performance status ≤ 2

          -  Patient must meet protocol-specified laboratory values

        Exclusion Criteria:

          -  Patients with brain cancer

          -  Patients who have concurrent severe and/or uncontrolled medical conditions which could
             compromise participation in the study

          -  Patients who have not recovered from previous anti-cancer therapies

          -  Female patients who are pregnant, breast feeding, or not willing to use an effective
             method of birth control

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00555672 (phase 1, status: completed)
Conditions: stomach neoplasms
ICD codes: D13.1, C16.9, C16.1, C16.2, D37.1, C16.8, C16.5
Drugs: 5-fluorouracil, cisplatin, sunitinib malate
SMILES: FC1=CNC(=O)NC1=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  confirmed diagnosis of stomach cancer

          -  advanced stomach cancer stage IV

          -  adequate blood chemistry, blood counts and kidney function

          -  willing to participate to study requirements and to sign an informed consent document

        Exclusion Criteria:

          -  prior chemotherapy for stomach cancer in its advanced stage

          -  excessive toxicities related to prior therapies

          -  pregnant or breastfeeding patients
Clinical trial NCT02182401 (phase 1, status: terminated)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: bi 207127 na, bi 201335 na, midazolam, tolbutamide
SMILES: CC1=CC(O)=CC(C)=C1Cl, CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy males (caucasian)

          -  Age ranging ≥ 21 and ≤ 50 years

          -  Body mass index (BMI) ≥ 19 and ≤ 29.9 kg/m2

          -  Willing to complete all study-related activities

          -  Volunteers give their written informed consent prior to admission to the study

        Exclusion criteria:

          -  Any finding of the medical examination (including blood pressure, pulse rate and
             electrocardiogram) deviating from normal and of clinical relevance

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders, clinically relevant electrolyte disturbances

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of photosensitivity or recurrent rash

          -  History of orthostatic hypotension, fainting spells or blackouts

          -  Chronic or clinically relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  Intake of drugs with a long half-life (> 24:00 hours) within at least one month or
             less than ten half-lives of the respective drug before enrolment in the study or
             during the study

          -  Use of any drugs which might influence the results of the trial up to 7 days prior to
             enrolment in the trial or during the trial

          -  vulnerable subjects (that is persons kept in detention)

          -  exclusion of contraindications or hypersensitivity to midazolam and / or tolbutamide

          -  Participation in another trial with an investigational drug (within two months prior
             to administration or during the trial)

          -  Smoker (> 10 cigarettes or > 3 cigars of > 3 pipes/day)

          -  Inability to refrain from smoking on trial days

          -  Alcohol abuse (> 60 g/day)

          -  Drug abuse

          -  Blood donation (> 100 mL within four weeks prior to administration or during the
             trial)

          -  Any laboratory value outside the reference range if indicative of underlying disease
             or poor health

          -  Excessive physical activities within the last week before the trial or during the
             trial

          -  Hypersensitivity to treatment medication and/or related drugs of these classes

          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTcF, or QTcB interval >450 ms)

          -  Homozygous carriers of the UGT1A1 (uridine diphosphate glucuronosyltransferase 1A1)
             enzyme polymorphism *28 and *60